WS #16776
Pfizer delivered stable Q3 revenue of $16.6 billion and announced new cost-cutting measures, providing a defensive anchor in the healthcare sector amidst broader market weakness. In M&A news, the all-stock merger between Marvell and Lumentum has caused double-digit plunges in both shares, reflecting investor skepticism about the strategic rationale and integration risks. This highlights a divergence between stable, cash-generative incumbents and volatile, speculative merger plays.
Healthcare Stability and M&A
Pfizer delivered stable Q3 revenue of $16.6 billion and announced new cost-cutting measures, providing a defensive anchor in the healthcare sector amidst broader market weakness. In M&A news, the all-stock merger between Marvell and Lumentum has caused double-digit plunges in both shares, reflecting investor skepticism about the strategic rationale and integration risks. This highlights a divergence between stable, cash-generative incumbents and volatile, speculative merger plays.